BPMC vs. APLS, IONS, OGN, ELAN, BBIO, CYTK, JAZZ, MDGL, NUVL, and ALPN
Should you be buying Blueprint Medicines stock or one of its competitors? The main competitors of Blueprint Medicines include Apellis Pharmaceuticals (APLS), Ionis Pharmaceuticals (IONS), Organon & Co. (OGN), Elanco Animal Health (ELAN), BridgeBio Pharma (BBIO), Cytokinetics (CYTK), Jazz Pharmaceuticals (JAZZ), Madrigal Pharmaceuticals (MDGL), Nuvalent (NUVL), and Alpine Immune Sciences (ALPN). These companies are all part of the "pharmaceutical preparations" industry.
Apellis Pharmaceuticals (NASDAQ:APLS) and Blueprint Medicines (NASDAQ:BPMC) are both mid-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, profitability, risk, community ranking, institutional ownership, earnings, analyst recommendations, valuation and dividends.
96.3% of Apellis Pharmaceuticals shares are held by institutional investors. 7.5% of Apellis Pharmaceuticals shares are held by insiders. Comparatively, 3.9% of Blueprint Medicines shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Blueprint Medicines received 202 more outperform votes than Apellis Pharmaceuticals when rated by MarketBeat users. Likewise, 68.21% of users gave Blueprint Medicines an outperform vote while only 67.17% of users gave Apellis Pharmaceuticals an outperform vote.
Apellis Pharmaceuticals currently has a consensus price target of $77.40, indicating a potential upside of 62.98%. Blueprint Medicines has a consensus price target of $91.57, indicating a potential downside of 14.42%. Given Blueprint Medicines' stronger consensus rating and higher probable upside, equities analysts plainly believe Apellis Pharmaceuticals is more favorable than Blueprint Medicines.
Blueprint Medicines has lower revenue, but higher earnings than Apellis Pharmaceuticals. Blueprint Medicines is trading at a lower price-to-earnings ratio than Apellis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
In the previous week, Blueprint Medicines had 3 more articles in the media than Apellis Pharmaceuticals. MarketBeat recorded 28 mentions for Blueprint Medicines and 25 mentions for Apellis Pharmaceuticals. Apellis Pharmaceuticals' average media sentiment score of 0.38 beat Blueprint Medicines' score of 0.19 indicating that Blueprint Medicines is being referred to more favorably in the news media.
Apellis Pharmaceuticals has a net margin of -133.34% compared to Apellis Pharmaceuticals' net margin of -203.30%. Blueprint Medicines' return on equity of -178.60% beat Apellis Pharmaceuticals' return on equity.
Apellis Pharmaceuticals has a beta of 0.97, indicating that its share price is 3% less volatile than the S&P 500. Comparatively, Blueprint Medicines has a beta of 0.65, indicating that its share price is 35% less volatile than the S&P 500.
Summary
Apellis Pharmaceuticals beats Blueprint Medicines on 11 of the 18 factors compared between the two stocks.
Get Blueprint Medicines News Delivered to You Automatically
Sign up to receive the latest news and ratings for BPMC and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BPMC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Blueprint Medicines Competitors List
Related Companies and Tools
